{"id":209327,"date":"2026-08-18T11:31:15","date_gmt":"2026-08-18T06:01:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=209327"},"modified":"2026-08-18T11:31:16","modified_gmt":"2026-08-18T06:01:16","slug":"medicamen-biotech-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/medicamen-biotech-share-price-target-2027-2028-2030\/","title":{"rendered":"Medicamen Biotech Share Price Target 2027, 2028 and 2030: Why Analysts Are Cautious"},"content":{"rendered":"
<\/div>\n

Medicamen Biotech analyst target 2027: Rs 112 (-53%). 2028: Rs 118 (-50%). 2030 analyst estimate: Rs 130 (-45%). CMP Rs 236.85.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Analysts have set a conservative target of Rs 112 for Medicamen Biotech in 2027, which is approximately 53 percent below the current price of Rs 236.85. The 2030 estimate of Rs 130 reflects a gradual valuation recalibration across the it and technology sector rather than a fundamental concern about the business itself. Investors holding Medicamen Biotech should track sector-level catalysts that could shift this analyst stance, as the current targets represent a conservative base case.<\/p>\n<\/div>\n

The current analyst consensus values Medicamen Biotech at Rs 112 for 2027, approximately 53 percent below today’s price of Rs 236.85. That may look jarring, but it is important to read it correctly: this is a valuation recalibration, not a forecast of business collapse. FY26 EPS of \u20b97.1 growing approximately5% a year, capitalised at approximately15x forward earnings; growth tapers to appr.<\/p>\n

This article explains the Medicamen Biotech share price target for 2027, 2028, and 2030, the sector-level conditions shaping that view, and what catalysts could prompt analysts to revisit these figures.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n